News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
753,710 Results
Type
Article (48631)
Company Profile (321)
Press Release (704735)
Multimedia
Podcasts (129)
Webinars (23)
Section
Business (210017)
Career Advice (2218)
Deals (36213)
Drug Delivery (149)
Drug Development (82876)
Employer Resources (197)
FDA (16706)
Job Trends (15391)
News (354428)
Policy (33487)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2787)
Academic (2)
Accelerated approval (47)
Adcomms (29)
Allergies (173)
Alliances (51159)
ALS (214)
Alzheimer's disease (1851)
Antibody-drug conjugate (ADC) (459)
Approvals (17064)
Artificial intelligence (701)
Autoimmune disease (296)
Automation (57)
Bankruptcy (368)
Best Places to Work (11831)
BIOSECURE Act (21)
Biosimilars (222)
Biotechnology (199)
Bladder cancer (189)
Brain cancer (72)
Breast cancer (758)
Cancer (5869)
Cardiovascular disease (475)
Career advice (1890)
Career pathing (47)
CAR-T (347)
CDC (64)
Celiac Disease (3)
Cell therapy (938)
Cervical cancer (48)
Clinical research (71592)
Collaboration (2121)
Company closure (5)
Compensation (1393)
Complete response letters (82)
COVID-19 (2825)
CRISPR (111)
C-suite (1157)
Cystic fibrosis (153)
Data (7914)
Decentralized trials (3)
Denatured (45)
Depression (165)
Dermatology (86)
Diabetes (591)
Diagnostics (7088)
Digital health (54)
Diversity (13)
Diversity, equity & inclusion (48)
Drug discovery (336)
Drug pricing (213)
Drug shortages (32)
Duchenne muscular dystrophy (289)
Earnings (93015)
Editorial (70)
Employer branding (25)
Employer resources (167)
Events (123179)
Executive appointments (1113)
FDA (20443)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (16)
Frontotemporal dementia (34)
Funding (1777)
Gene editing (244)
Generative AI (61)
Gene therapy (746)
GLP-1 (1104)
Government (4908)
Grass and pollen (6)
Guidances (409)
Healthcare (19382)
HIV (85)
Huntington's disease (59)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (99)
Immunology and inflammation (299)
Immuno-oncology (94)
Indications (191)
Infectious disease (3170)
Inflammatory bowel disease (224)
Inflation Reduction Act (17)
Influenza (137)
Intellectual property (293)
Interviews (353)
IPO (16881)
IRA (53)
Job creations (3861)
Job search strategy (1579)
JPM (63)
Kidney cancer (19)
Labor market (109)
Layoffs (592)
Leadership (43)
Legal (8118)
Liver cancer (100)
Longevity (32)
Lung cancer (772)
Lymphoma (433)
Machine learning (62)
Management (63)
Manufacturing (1069)
MASH (191)
Medical device (14090)
Medtech (14213)
Mergers & acquisitions (20579)
Metabolic disorders (1532)
mRNA (215)
Multiple sclerosis (189)
NASH (23)
Neurodegenerative disease (430)
Neuropsychiatric disorders (108)
Neuroscience (3389)
Neurotech (1)
NextGen: Class of 2026 (6729)
Non-profit (4702)
Now hiring (79)
Obesity (725)
Opinion (312)
Ovarian cancer (223)
Pain (259)
Pancreatic cancer (302)
Parkinson's disease (367)
Partnered (35)
Patents (598)
Patient recruitment (674)
Peanut (64)
People (61662)
Pharmaceutical (70)
Pharmacy benefit managers (32)
Phase 1 (22319)
Phase 2 (31521)
Phase 3 (23456)
Pipeline (8755)
Policy (337)
Postmarket research (2648)
Preclinical (9744)
Press Release (72)
Prostate cancer (301)
Psychedelics (57)
Radiopharmaceuticals (326)
Rare diseases (1091)
Real estate (6296)
Recruiting (77)
Regulatory (25873)
Reports (72)
Research institute (2576)
Resumes & cover letters (378)
Rett syndrome (39)
RNA editing (22)
RSV (90)
Schizophrenia (181)
Series A (303)
Series B (219)
Service/supplier (13)
Sickle cell disease (117)
Special edition (27)
Spinal muscular atrophy (169)
Sponsored (49)
Startups (3848)
State (2)
Stomach cancer (19)
Supply chain (129)
Tariffs (87)
The Weekly (81)
Vaccines (1134)
Venture capital (116)
Weight loss (473)
Women's health (127)
Worklife (22)
Date
Today (48)
Last 7 days (864)
Last 30 days (3516)
Last 365 days (30635)
2026 (12639)
2025 (30761)
2024 (35948)
2023 (40861)
2022 (51927)
2021 (56500)
2020 (54899)
2019 (47647)
2018 (35939)
2017 (33097)
2016 (32677)
2015 (38781)
2014 (32378)
2013 (27541)
2012 (29798)
2011 (30537)
2010 (29032)
Location
Africa (820)
Alabama (95)
Alaska (7)
Arizona (359)
Arkansas (15)
Asia (41395)
Australia (6829)
California (13372)
Canada (3795)
China (1355)
Colorado (577)
Connecticut (582)
Delaware (405)
Europe (90644)
Florida (1990)
Georgia (438)
Hawaii (4)
Idaho (63)
Illinois (1070)
India (92)
Indiana (613)
Iowa (24)
Japan (542)
Kansas (134)
Kentucky (52)
Louisiana (41)
Maine (76)
Maryland (1605)
Massachusetts (9615)
Michigan (385)
Minnesota (742)
Mississippi (7)
Missouri (146)
Montana (33)
Nebraska (29)
Nevada (145)
New Hampshire (86)
New Jersey (3540)
New Mexico (31)
New York (3517)
North Carolina (1740)
North Dakota (11)
Northern California (6688)
Ohio (403)
Oklahoma (24)
Oregon (42)
Pennsylvania (2683)
Puerto Rico (29)
Rhode Island (50)
South America (1191)
South Carolina (85)
South Dakota (2)
Southern California (5268)
Tennessee (213)
Texas (2146)
United States (47437)
Utah (400)
Vermont (1)
Virginia (327)
Washington D.C. (85)
Washington State (1075)
West Virginia (4)
Wisconsin (142)
Wyoming (2)
753,710 Results for "gilead sciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lung cancer
Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls
The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in lung cancer.
April 21, 2026
·
2 min read
·
Tristan Manalac
Earnings
Gilead sets blockbuster bar for Yeztugo’s first full year on the market
With initial patients coming back for their second dose of Gilead’s twice-yearly PrEP injection, the pharma thinks the shot will hit $1 billion in sales this year, serving as “a cornerstone in Gilead’s revenue growth story.”
May 8, 2026
·
2 min read
·
Tristan Manalac
Layoffs
Gilead wipes out most of Arcellx workforce
Gilead is laying off Arcellx employees in California and Maryland, with some cuts effective this year and the remainder happening in 2027.
May 7, 2026
·
1 min read
·
Angela Gabriel
Press Releases
Gilead Sciences Announces First Quarter Financial Results
May 8, 2026
·
19 min read
Mergers & acquisitions
Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis
The acquisition of Tubulis GmbH—Gilead Sciences’ latest of the year after buying Arcellx and Ouro Medicines—brings into the fold a novel ovarian cancer candidate that has demonstrated promising mid-stage data.
April 7, 2026
·
2 min read
·
Heather McKenzie
Mergers & acquisitions
Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities
Gilead Sciences has inked three deals this year so far totaling $14.77 billion, a marked escalation of the company’s usual M&A pace. Executives detailed the rationale for buying Arcellx, Ouro Medicine and Tubulis GmbH and whether they are interested in further deals.
April 8, 2026
·
5 min read
·
Annalee Armstrong
Press Releases
Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
May 1, 2026
·
1 min read
People
Gilead Chief Gets 20% Pay Bump, Still Falls Short of $30M Club
Gilead’s median employee compensation in 2025 was $238,979. Daniel O’Day’s compensation package is 119 times larger.
March 24, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
April 28, 2026
·
7 min read
Mergers & acquisitions
Gilead Drops $2.1B for Ouro, Hopes To Split Cost with Galapagos
Following last month’s $7.8 billion purchase of CAR T biotech Arcellx, Gilead’s dealmaking train chugs along with yet another acquisition—this time securing Ouro Medicines’ pipeline of T cell engagers for inflammatory diseases.
March 24, 2026
·
3 min read
·
Tristan Manalac
1 of 75,371
Next
